famciclovir | Famvir tablets 125 mg, 10 pcs.

Release form

White coated tablets, round, biconvex, with beveled edges, with FV engraving on one side and 125 on the other.

Packing

Per pack of 10

Pharmacological action

Famvir - an antiviral drug. After oral administration, famciclovir quickly turns into penciclovir, which is active against human herpes viruses, including Varicella zoster virus (herpes zoster virus) and Herpes simplex types 1 and 2 (herpes simplex and genital virus), as well as Epstein-Barr virus and cytomegalovirus . Penciclovir enters the virus-infected cells, where, under the action of viral thymidine kinase, it quickly turns into monophosphate, which, in turn, with the participation of cellular enzymes passes into triphosphate. Penciclovir triphosphate is present in virus-infected cells for more than 12 hours, inhibiting viral DNA replication in them. The concentration of penciclovir triphosphate in uninfected cells does not exceed the minimum determined, therefore, at therapeutic concentrations, penciclovir does not affect uninfected cells.

Penciclovir is active against recently discovered acyclovir-resistant strains of Herpes simplex virus with altered DNA polymerase. The incidence of resistance to famciclovir (penciclovir) does not exceed 0.3%, in patients with impaired immunity - 0.19%. Resistance was detected at the beginning of treatment and did not develop during treatment or after the end of therapy. It was shown that famciclovir significantly reduces the severity and duration of postherpetic neuralgia in patients with herpes zoster.

It was shown that in patients with immunity due to HIV infection, famciclovir at a dose of 500 mg 2 times / day reduces the number of days of isolation of the herpes simplex virus (both with clinical manifestations and without them).

Indications

- Infections caused by the Varicella zoster virus (herpes zoster), including ophthalmic herpes and postherpetic neuralgia.

- Herpes simplex virus infections (types 1 and 2): primary infection, exacerbation of chronic infection, suppression of recurrent infection (for the prevention of exacerbations).

- Infections caused by Varicella zoster and Herpes simplex viruses (types 1 and 2) in immunocompromised patients.

Contraindications

- Hypersensitivity to famciclovir or any of the components of the drug.

- Hypersensitivity to penciclovir.

Use during pregnancy and lactation

Since the safety of Famvir in pregnant and lactating women has not been studied, its use during pregnancy and lactation is not recommended, unless the possible treatment benefits do not exceed the potential risk. It is not known whether penciclovir with breast milk is excreted in humans. Famciclovir does not have a pronounced effect on the spermogram, morphology, or motility of human sperm. In experimental studies, no embryotoxic and teratogenic effects of famciclovir and penciclovir were detected. Studies in rats administered famciclovir orally showed that penciclovir is excreted in breast milk. A decrease in fertility was noted in the experimental model in male rats treated with famciclovir at a dose of 500 mg / kg body weight, in female rats a marked decrease in fertility was not observed.

Composition

1 tablet contains: famciclovir 125 mg.

Excipients: hydroxypropyl cellulose, anhydrous lactose, sodium starch glycolate, magnesium stearate.

Shell composition: hypromellose, titanium dioxide, polyethylene glycol 4000 (macrogol), polyethylene glycol 6000 (macrogol).

Side effects of

In clinical studies, Famvir is well tolerated, including in patients with reduced immunity. Cases of headache and nausea have been reported however, these phenomena were mild or moderate and were observed with the same frequency in patients receiving placebo.

The following are adverse reactions and their frequency of occurrence based on data on spontaneous reports, as well as cases described in the literature, for the entire period during which Famvir is used in clinical practice. Adverse events reported during clinical trials in patients with reduced immunity coincided with those observed in patients with normal immunity.

The following criteria were used to assess the incidence of adverse reactions: very often (> 1/10) often (from> 1/100, <1/10) sometimes (> 1/1000, 1/10000, <1/1000) very rarely (<1/10000), including individual messages.

From the hemopoietic system: very rarely - thrombocytopenia.

From the side of the central nervous system: rarely - headache, confusion (mainly in elderly patients) very rarely - dizziness, drowsiness (mainly in elderly patients), hallucinations.

From the digestive system: rarely - nausea very rarely - vomiting, jaundice.

Dermatological reactions: very rarely - rash, itching, severe skin reactions.

Allergic reactions: very rarely - urticaria, severe skin reactions (including erythema multiforme).



overdose The reported cases of overdose (10.5 g) of the Famvir drug were not accompanied by clinical manifestations.

Treatment: carrying out symptomatic and supportive therapy. Failure to follow the recommendations to reduce the dose of famciclovir, taking into account renal function in patients with kidney disease, noted cases of acute renal failure.

Penciclovir is excreted in hemodialysis. Penticlovir plasma concentrations decreased by 75% after hemodialysis for 4.

active substance

Famciclovir

Pharmacy Terms

In retseptu

The dosage form of

tablet

Indications

Herpes, Herpes zoster, Genital herpes, Chickenpox

Possible product names

FAMVIR 0.125 N10 TABLE P / O

Famvir 125mg Tab. sachel Xp

Famvir 125mg No. 10 tab

Famvir sachet p / o 125mg N10

Famvir sachet p / o 125mg x 10